Sun to Acquire Taro for US$454 M
Business Review Editor
Abstract
Sun Pharmaceuticals acquired Taro Pharmaceutical Industries, substantially expanding its product portfolio with dermatology and pediatrics generics. The deal would worth up to US$454 M to Taro.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.